NCT01531309View on ClinicalTrials.gov

Pharmacokinetics of AGO178 in Participants With Liver Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 8, 2011

Primary Completion Date

September 2, 2011

Study Completion Date

September 2, 2011

Conditions
Hepatic Impairment
Interventions
DRUG

AGO178

AGO178 is administered as a sublingual tablet.

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY